The new Kronos IEMs from have nine drivers and a six-way crossover but an impedance of less than 35Ω. Noble Audio has announced the launch of its latest pair of flagship in-ear monitors. The Kronos ...

Noble Kronos flagship IEMs deliver cutting-edge 9-driver hybrid sound with titanium shells. Are these $4,500 earphones worth the hype and price? Now, before you roll your eyes at the $4,500 price tag ...

Kronos is a HOLD: TiO2 demand should rise, but KRO lacks operating leverage and control over key feedstocks to benefit from upside. KRO faces significant competition from Chinese producers, especially ...

Today (July 16) marks the 80th anniversary of the Trinity test, during which a team of U.S. scientists led by J. Robert Oppenheimer detonated the world’s first atomic bomb in the deserts of New Mexico ...

Get the latest federal technology news delivered to your inbox. The Department of Veterans Affairs is moving forward with efforts to modernize its appointment scheduling systems but should take ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Jennifer A. Ligibel, MD, professor at Harvard Medical School and senior physician in ...

With the walls quickly closing in, Kronos Bio has accepted a buyout from notorious biotech acquirer Concentra Biosciences. Tang Capital Partners’ Concentra inked a definitive deal to acquire Kronos’ ...

(RTTNews) - Kronos Bio (KRON) has entered into a definitive merger agreement with Concentra Biosciences, LLC, whereby Concentra will acquire Kronos Bio for $0.57 in cash per share of Kronos Bio common ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Matthew Guay It’s hard not to feel scatterbrained in today’s work environment.

Self-scheduling has redefined patient access, moving beyond convenience to become a competitive advantage. It allows patients to book, reschedule, and manage appointments on their own terms, meeting ...

Kronos Bio, a San Mateo biotech company, is losing millions of dollars a month and recently had to discontinue its sole clinical-stage compound because of adverse side effects. Now, the company is ...